News & Videos - TARO PHARMACEUTICAL INDUSTRIES

Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited. PR Newswire MILWAUKEE, May 20, 2024 MILWAUKEE , May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun . Click here to learn how...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2023. Quarter ended June 30, 2023 Highlights ─ compared to June 30, 2022 Net sales increased $2.2 million, or 1.4%, to $158.9 million. Gross profit of $64.1 million (40.3% of net sales) compared to $81.6 million (52.1% of net sales). Research and development (R&D) expenses of $16.1 million increased $4.6 million. Selling, marketing,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to March 31, 2022 Net sales of $146.6 million increased $3.3 million, or 2.3%. Gross profit of $75.7 million (51.6% of net sales) compared to $77.3 million (54.0% of net sales). Research and development (R&D) expenses of $16.3 million increased $1.4 million. Selling,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022. Quarter ended December 31, 2022* Highlights ─ compared to December 31, 2021 Net sales of $139.2 million was line with the prior year quarter. We continue to experience price pressures particularly in the U.S. generic business. Gross profit of $64.0 million (46.0% of net sales) compared to $76.0 million (54.7% of...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2022. Quarter ended September 30, 2022* Highlights ─ compared to September 30, 2021 Net sales of $130.5 million decreased, principally due to the continued price decline particularly in the U.S. generic business, as well as a one-time gross-to-net (“GTN”) adjustment. Gross profit of $47.0 million (36.0% of net...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June 30, 2021 Net sales increased $9.6 million, or 6.5%, to $156.7 million. Gross profit of $81.6 million (52.1% of net sales) compared to $77.7 million (52.8% of net sales). Research and development (R&D) expenses of $11.5 million decreased $1.4 million. Selling, marketing,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28 th acquisition of Alchemee. Net sales of $143.3 million decreased $5.1 million. Gross profit of $77.3 million (54.0% of net sales) compared to $76.9 million (51.9% of net...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the completion of its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv ® brand. “This acquisition demonstrates Taro’s commitment to strengthening our position in the over-the-counter dermatology space,” said Uday Baldota, Taro’s CEO. “In addition to adding Proactiv ® to our product...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2021. Quarter ended December 31, 2021 Highlights ─ compared to December 31, 2020 Net sales of $139.0 million decreased $1.2 million. Gross profit of $76.0 million increased $2.8 million, and as a percentage of net sales was 54.7% compared to 52.2%. Research and development (“R&D”) expenses of $14.2 million were in...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2021, after the close of market on Thursday, January 27, 2022. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today. Mr. Coote has over 25 years of significant financial executive experience; most recently serving as Taro’s AVP, Treasurer and Business Finance since 2008. Prior to joining Taro, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co.,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2021. Quarter ended September 30, 2021 Highlights ─ compared to September 30, 2020 Net sales of $132.0 million decreased $10.9 million. Gross profit of $62.0 million (47.0% of net sales compared to 57.1%) decreased $19.5 million. Research and development (“R&D”) expenses of $12.5 million decreased $4.1 million....